Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Ordinary Shares, nominal value Euro 0.12 per share
-
Shares outstanding
-
114,390,553
-
Number of holders
-
29
-
Total 13F shares, excl. options
-
48,833,993
-
Shares change
-
+15,486,597
-
Total reported value, excl. options
-
$580,635,231
-
Value change
-
+$184,129,037
-
Number of buys
-
23
-
Number of sells
-
2
-
Price
-
$11.89
Institutional Holders of NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value Euro 0.12 per share (NAMS) as of Q2 2023
As of 30 Jun 2023 NewAmsterdam Pharma Co N.V. - Ordinary Shares, nominal value Euro 0.12 per share (NAMS) had 29 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 48,833,993 shares of stock of the company.
Largest 10 holders included Frazier Life Sciences Management, L.P., Bain Capital Life Sciences Investors, LLC, RA CAPITAL MANAGEMENT, L.P., VIKING GLOBAL INVESTORS LP, Medicxi Ventures Management (Jersey) Ltd, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), BVF INC/IL, GMT CAPITAL CORP, ADAGE CAPITAL PARTNERS GP, L.L.C., and Eversept Partners, LP.
This table shows 29 institutional shareholders of the security as of 30 Jun 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.